Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 2:39 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 506820 | NSE: ASTRAZEN

Astrazeneca Pharma India Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹5,726.65Overvalued by 27.07%vs CMP ₹7,852.00

P/E (94.4) × ROE (23.6%) × BV (₹320.00) × DY (0.41%)

₹2,193.34Overvalued by 72.07%vs CMP ₹7,852.00
MoS: -258% (Negative)Confidence: 66/100 (Moderate)Models: 1 Fair, 9 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹7,254.0521%Fair (-7.6%)
Graham NumberEarnings₹760.6515%Over (-90.3%)
Earnings PowerEarnings₹388.7810%Over (-95%)
DCFCash Flow₹1,958.5610%Over (-75.1%)
Net Asset ValueAssets₹319.607%Over (-95.9%)
EV/EBITDAEnterprise₹1,397.208%Over (-82.2%)
Dividend DiscountDividends₹110.008%Over (-98.6%)
Earnings YieldEarnings₹803.607%Over (-89.8%)
ROCE CapitalReturns₹756.168%Over (-90.4%)
Revenue MultipleRevenue₹1,029.605%Over (-86.9%)
Consensus (10 models)₹2,193.34100%Overvalued
Key Drivers: EPS CAGR 26.7% lifts DCF — verify sustainability. | Wide model spread (₹110–₹7,254) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 26.7%

*Investments are subject to market risks

Investment Snapshot

76
Astrazeneca Pharma India Ltd scores 76/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health92/100 · Strong
ROCE 33.4% ExcellentROE 23.6% ExcellentD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money65/100 · Strong
FII holding stable No changeDII holding up 0.90% MF buyingPromoter holding at 75.0% Stable
Earnings Quality50/100 · Moderate
OPM stable around 15% Steady
Quarterly Momentum90/100 · Strong
Revenue (4Q): +35% YoY AcceleratingProfit (4Q): +146% YoY Strong
Industry Rank75/100 · Strong
P/E 94.4 vs industry 53.8 Premium to peersROCE 33.4% vs industry 16.4% Above peersROE 23.6% vs industry 15.2% Above peers3Y sales CAGR: 29% High growth

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 2:39 am

Market Cap 19,630 Cr.
Current Price 7,852
Intrinsic Value₹2,193.34
High / Low 10,691/6,502
Stock P/E94.4
Book Value 320
Dividend Yield0.41 %
ROCE33.4 %
ROE23.6 %
Face Value 2.00
PEG Ratio3.54

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Astrazeneca Pharma India Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Astrazeneca Pharma India Ltd 19,630 Cr. 7,852 10,691/6,50294.4 3200.41 %33.4 %23.6 % 2.00
Acutaas Chemicals Ltd 19,093 Cr. 2,332 2,688/93066.5 1730.06 %19.9 %16.0 % 5.00
Wockhardt Ltd 20,598 Cr. 1,268 1,870/1,087190 2810.00 %3.75 %1.22 % 5.00
ERIS Lifesciences Ltd 18,152 Cr. 1,310 1,910/1,09740.9 2270.56 %12.2 %12.9 % 1.00
Natco Pharma Ltd 17,945 Cr. 1,002 1,060/66011.5 4830.60 %32.8 %28.0 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Astrazeneca Pharma India Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 236250285295311306383388408440480526559
Expenses 195213225228258291334349355363394445484
Operating Profit 41376067531549385377868175
OPM % 17%15%21%23%17%5%13%10%13%17%18%15%13%
Other Income 77-32825109-498-2610111
Interest 000001-0000111
Depreciation 344444449918173
Profit before tax 44392371732054-155142787573
Tax % 26%26%26%25%29%23%27%-22%25%27%26%25%26%
Net Profit 33291754521639-123831585654
EPS in Rs 13.0211.726.9121.5420.956.3215.79-4.7215.3712.3423.3022.3321.69

Last Updated: January 2, 2026, 9:31 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 23, 2026, 10:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 4745175645445717288328148061,0031,2961,7162,177
Expenses 4875285475065256577116787198381,1111,4621,890
Operating Profit -13-111637467112113586165184254287
OPM % -3%-2%3%7%8%10%15%17%11%16%14%15%13%
Other Income 2367141216131315-1451-5629
Interest 0000001111113
Depreciation 10151716151519201716154041
Profit before tax 0-21636447311412783134220156273
Tax % 0%9%44%41%25%37%27%26%26%26%26%
Net Profit -1-21520265472936299162116201
EPS in Rs -0.20-8.342.108.0210.3621.7828.8837.3224.6439.7264.6046.3080.36
Dividend Payout % 0%0%0%0%0%0%3%5%41%40%37%69%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-2000.00%123.81%300.00%30.00%107.69%33.33%29.17%-33.33%59.68%63.64%-28.40%
Change in YoY Net Profit Growth (%)0.00%2123.81%176.19%-270.00%77.69%-74.36%-4.17%-62.50%93.01%3.96%-92.03%

Astrazeneca Pharma India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:13%
5 Years:16%
3 Years:29%
TTM:34%
Compounded Profit Growth
10 Years:26%
5 Years:19%
3 Years:43%
TTM:61%
Stock Price CAGR
10 Years:23%
5 Years:19%
3 Years:44%
1 Year:32%
Return on Equity
10 Years:19%
5 Years:21%
3 Years:23%
Last Year:24%

Last Updated: September 4, 2025, 11:55 pm

Balance Sheet

Last Updated: December 4, 2025, 12:59 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 5555555555555
Reserves 167146151218242296359451506584707765794
Borrowings 00000012129753635
Other Liabilities 244261247193214261330306337389362712781
Total Liabilities 4164124034154615627067758579851,0781,5181,615
Fixed Assets 941019787757572817469676440
CWIP 912654724421000
Investments 0000000000000
Other Assets 3122982993243824806116907809151,0111,4541,575
Total Assets 4164124034154615627067758579851,0781,5181,615

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -1-46573895587105101582865
Cash from Investing Activity + -15-19-40-94-1711735182231
Cash from Financing Activity + 860-1000-6-9-9-24-44-66
Net Cash Flow 71-645338-159-902699652531
Free Cash Flow -19-694833337749994531864
CFO/OP -52%393%365%133%28%126%100%101%146%60%46%51%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-13.00-11.0016.0037.0046.0071.00109.00123.0077.00158.00179.00218.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 413054293540373839394339
Inventory Days 210157141121229186197198164193140208
Days Payable 241203174184257266251221223231121173
Cash Conversion Cycle 10-1621-347-39-1715-2016274
Working Capital Days -45-15-28-36-8-14-16-17-34-182022
ROCE %-12%-13%4%15%19%27%34%30%16%31%31%33%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%
FIIs 2.70%2.68%2.69%2.66%2.73%2.79%2.90%2.92%2.89%3.03%2.74%2.71%
DIIs 1.41%1.91%2.42%2.76%3.77%4.99%5.08%5.21%4.65%4.55%5.26%5.55%
Public 20.88%20.40%19.89%19.57%18.50%17.21%17.02%16.85%17.45%17.41%17.00%16.73%
No. of Shareholders 42,14638,94632,38029,03229,41827,16927,61527,32232,46634,37832,91431,551

Shareholding Pattern Chart

No. of Shareholders

Astrazeneca Pharma India Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Small Cap Fund 659,875 0.86 564.19658,0752026-02-22 10:32:570.27%
Bandhan Large & Mid Cap Fund 127,498 0.78 109.01110,6372026-02-23 05:56:3115.24%
Bandhan Innovation Fund 85,237 3.81 72.8883,9642026-02-22 00:09:031.52%
Nippon India Pharma Fund 62,568 0.68 53.511,5612025-12-08 04:19:42441.2%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund 58,282 0.75 49.8355,0212026-02-22 10:32:575.93%
Baroda BNP Paribas Small Cap Fund 32,200 2.36 27.53N/AN/AN/A
Baroda BNP Paribas Manufacturing Fund 27,900 2.65 23.8530,6002026-02-23 08:14:38-8.82%
ICICI Prudential Multicap Fund 27,260 0.15 23.3122,0902026-02-22 10:32:5723.4%
ICICI Prudential Smallcap Fund 21,370 0.22 18.2718,8702026-02-22 10:32:5713.25%
Bandhan Aggressive Hybrid Fund 21,217 1.11 18.1420,0442026-02-23 02:46:195.85%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 46.3064.6039.7024.6037.30
Diluted EPS (Rs.) 46.3064.6039.7024.6037.30
Cash EPS (Rs.) 62.2970.5846.2231.4245.37
Book Value[Excl.RevalReserv]/Share (Rs.) 308.14284.77235.48204.56182.47
Book Value[Incl.RevalReserv]/Share (Rs.) 308.14284.77235.48204.56182.47
Dividend / Share (Rs.) 32.0024.0016.0010.002.00
Revenue From Operations / Share (Rs.) 686.52518.21401.19322.24325.42
PBDIT / Share (Rs.) 117.8487.7076.4940.3859.32
PBIT / Share (Rs.) 101.8481.7269.9833.6051.27
PBT / Share (Rs.) 62.5487.8253.6433.2250.84
Net Profit / Share (Rs.) 46.3064.6039.7224.6437.32
PBDIT Margin (%) 17.1616.9219.0612.5218.22
PBIT Margin (%) 14.8315.7717.4410.4215.75
PBT Margin (%) 9.1116.9413.3710.3015.62
Net Profit Margin (%) 6.7412.469.897.6411.46
Return on Networth / Equity (%) 15.0222.6816.8612.0420.45
Return on Capital Employeed (%) 31.2328.3429.1116.0327.20
Return On Assets (%) 7.6214.9810.087.1912.04
Asset Turnover Ratio (%) 1.321.261.090.981.10
Current Ratio (X) 1.912.612.182.122.04
Quick Ratio (X) 1.131.971.681.701.51
Inventory Turnover Ratio (X) 4.420.610.510.590.59
Dividend Payout Ratio (NP) (%) 51.8424.7620.148.115.35
Dividend Payout Ratio (CP) (%) 38.5222.6617.306.364.40
Earning Retention Ratio (%) 48.1675.2479.8691.8994.65
Cash Earning Retention Ratio (%) 61.4877.3482.7093.6495.60
Interest Coverage Ratio (X) 201.78182.71303.52106.25136.06
Interest Coverage Ratio (Post Tax) (X) 146.57121.90222.4665.8486.60
Enterprise Value (Cr.) 20979.1812795.167617.775940.177173.15
EV / Net Operating Revenue (X) 12.229.887.607.378.82
EV / EBITDA (X) 71.2158.3639.8458.8548.37
MarketCap / Net Operating Revenue (X) 12.5410.278.097.939.25
Retention Ratios (%) 48.1575.2379.8591.8894.64
Price / BV (X) 27.9318.6813.7912.4916.50
Price / Net Operating Revenue (X) 12.5410.278.097.939.25
EarningsYield 0.010.010.010.010.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

AstraZeneca Pharma India Ltd. is a Public Limited Listed company incorporated on 11/07/1979 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is L24231KA1979PLC003563 and registration number is 003563. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1716.29 Cr. and Equity Capital is Rs. 5.00 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsBlock N1, 12th Floor, Bengaluru Karnataka 560045Contact not found
Management
NamePosition Held
Ms. Shilpa Divekar NirulaChairperson & Independent Director
Mr. Praveen Rao AkkinepallyManaging Director
Ms. Bhavana AgrawalExecutive Director
Ms. Sylvia Lorena Varela RamonNon Executive Director
Ms. Hooi Bien ChuahNon Executive Director
Mr. Jesus Javier Diaz-Ropero EstesoNon Executive Director
Ms. Revathy AshokIndependent Director
Ms. Monica WidhaniIndependent Director

FAQ

What is the intrinsic value of Astrazeneca Pharma India Ltd and is it undervalued?

As of 19 April 2026, Astrazeneca Pharma India Ltd's intrinsic value is ₹2193.34, which is 72.07% lower than the current market price of ₹7,852.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (23.6 %), book value (₹320), dividend yield (0.41 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Astrazeneca Pharma India Ltd?

Astrazeneca Pharma India Ltd is trading at ₹7,852.00 as of 19 April 2026, with a FY2026-2027 high of ₹10,691 and low of ₹6,502. The stock is currently in the middle of its 52-week range. Market cap stands at ₹19,630 Cr..

How does Astrazeneca Pharma India Ltd's P/E ratio compare to its industry?

Astrazeneca Pharma India Ltd has a P/E ratio of 94.4, which is above the industry average of 53.84. The premium over industry average may reflect growth expectations or speculative interest.

Is Astrazeneca Pharma India Ltd financially healthy?

Key indicators for Astrazeneca Pharma India Ltd: ROCE of 33.4 % indicates efficient capital utilization; ROE of 23.6 % shows strong shareholder returns. Dividend yield is 0.41 %.

Is Astrazeneca Pharma India Ltd profitable and how is the profit trend?

Astrazeneca Pharma India Ltd reported a net profit of ₹116 Cr in Mar 2025 on revenue of ₹1,716 Cr. Compared to ₹62 Cr in Mar 2022, the net profit shows an improving trend.

Does Astrazeneca Pharma India Ltd pay dividends?

Astrazeneca Pharma India Ltd has a dividend yield of 0.41 % at the current price of ₹7,852.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Astrazeneca Pharma India Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports